Peregrine Pharmaceuticals (PPHM), Sanofi SA (ADR) (SNY): Is This Experimental Lung Cancer Drug Back on Track?

Peregrine’s upside potential remains high
Monoclonal antibodies like bavituximab, cetuximab, and necitumumab are considered to be the next generation of cancer treatments, which could one day render chemotherapy obsolete. Monoclonal antibodies can be trained with precise tasks, such as blocking growth signals or even acting as “smart bombs” with toxic payloads (antibody drug conjugates) to tactically strike at cancer tumors. Chemotherapy, by comparison, inhibits the growth of both infected and healthy cells by using a “carpet bomb” approach.

The significance of Peregrine’s bavituximab is its unique strategy of targeting PS, which represents another new approach in the increasingly innovative field of cancer treatments. If Peregrine can successfully bring bavituximab to the market, it would be the first treatment of its kind and the company’s first approved drug. It could also be considered a safer alternative to Lilly’s necitumumab and chemotherapy treatments like Taxotere.

Until then, Peregrine will remain a speculative biotech stock with very little fundamental scaffolding, but its upside potential remains high.

The article Is This Experimental Lung Cancer Drug Back on Track? originally appeared on Fool.com.

Leo Sun has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.